Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [9][21] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [9] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [9] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [10][22] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [10][23] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [20] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in its global install base [11] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [11] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [6] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [6][7] Company Strategy and Development Direction - The company aims to shift its model from device placement to device utilization, focusing on unlocking the economic potential of its installed base [8] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [12][14] - The company plans to enhance its product ecosystem and strengthen its market position through disciplined innovation and targeted marketing efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [11] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half as execution initiatives take hold [17][24] - The company expects to return to growth in 2027, driven by operational changes and innovation [17][26] Other Important Information - The company ended 2025 with approximately $232.7 million in cash equivalents, a decrease from $370.1 million in 2024, primarily due to debt restructuring [21] - The company is focusing on improving its balance sheet and financial discipline, which has contributed to its stabilization [10][18] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D for future innovation [30][31] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points, impacting procedure volume and device placements [36][37] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with a focus on restructuring sales and customer service teams to better support smaller accounts [41][43] - The company is addressing the needs of new demographics, including men and Gen Z, by positioning HydraFacial as a lifestyle routine [45][46] Question: New system launch timeline and additional services - The next-generation HydraFacial is in early development, with a planned launch in 2028, aimed at providing compelling reasons for upgrades [51][52] Question: Consumables performance and pricing strategy - The company successfully implemented a 5% price increase on consumables without significant pushback, and is evaluating overall pricing strategy moving forward [74]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled approximately $318.1 million, up from approximately $151.5 million as of December 31, 2024 [24] - Revenue for Q4 2025 was $0, compared to approximately $11.1 million for Q4 2024, and for the full year 2025, revenue was also $0, down from approximately $22.3 million in 2024 [24] - Total operating expenses for Q4 2025 were approximately $29.2 million, compared to approximately $18.8 million for Q4 2024, with full-year operating expenses at approximately $108.1 million, up from approximately $64.8 million in 2024 [25] - Net loss for Q4 2025 was approximately $30.2 million, compared to a net loss of approximately $7.1 million for Q4 2024, and for the full year 2025, the net loss was approximately $105 million, compared to approximately $40.5 million in 2024 [26] Business Line Data and Key Metrics Changes - The company is focused on advancing Deramiocel for Duchenne muscular dystrophy (DMD), with a Biologics License Application (BLA) under review by the FDA [4][5] - The HOPE-3 trial showed significant results, including a 91% slowing of disease progression in left ventricular ejection fraction among evaluable patients [7][8] - The company aims to position Deramiocel to treat as many eligible patients as possible, with a focus on both skeletal and cardiac disease manifestations of DMD [5][6] Market Data and Key Metrics Changes - The FDA has accepted the BLA for review with a target action date of August 22, 2026, marking a significant regulatory milestone for the company [4][15] - The company is preparing for a potential commercial launch and has completed its FDA pre-license inspection for its manufacturing facility [16][17] Company Strategy and Development Direction - The company is building an infrastructure to support the launch and commercialization of Deramiocel while expanding its pipeline to treat other indications [6][19] - The company is also exploring expansion into other diseases, initially focusing on Becker muscular dystrophy [19] - The company is committed to maintaining a disciplined approach to execution and investing in its pipeline to operate as a world-class commercial biotech company [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the data and the company's manufacturing readiness, positioning it well for growth [6][15] - The company is focused on addressing the unmet needs of the DMD community and is preparing for a potential commercial launch [17][18] - Management highlighted the importance of the HOPE-3 trial data in supporting the therapeutic profile of Deramiocel [14][15] Other Important Information - The company ended 2025 with a strong cash position of approximately $318 million, which is expected to fund operations into the fourth quarter of 2027 [22] - The company has been approved for uplisting to the Nasdaq Global Select Market, enhancing visibility within the institutional investment community [23] Q&A Session Summary Question: Anticipation of Ad Com and commercial preparation for Deramiocel approval - Management indicated that there has been no movement towards an Advisory Committee meeting and expressed confidence in the strength of the HOPE-3 data regardless of the review process [30][32] Question: Clarification on the label for Deramiocel - Management believes the data supports a label for both DMD and cardiomyopathy, with ongoing discussions with the FDA [34][35] Question: Status of the two cohorts in the HOPE-3 trial - Management confirmed that the FDA considers the two cohorts as one trial and expressed confidence in the statistical significance of cohort B [39][41] Question: Expectations for the peer-reviewed publication of HOPE-3 data - Management stated that the academic review process is ongoing and updates will be provided once the publication is ready [42] Question: Insights from the Muscular Dystrophy Association meeting - Management noted that the HOPE-3 data has solidified belief in Deramiocel among physicians and increased inquiries about prescribing and availability [60] Question: Plans for scaling manufacturing capacity - Management confirmed plans for additional manufacturing build-out to accommodate more patients, contingent on the successful response to the BLA [66][67]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $10.9 million, marking a 23% year-over-year growth, and full-year revenue reached $41.1 million, a 22% increase from $33.6 million in 2024 [20][22] - The company achieved positive cash flow from operations for both Q3 and Q4, and for the full year, with cash ending at $8.9 million [10][24] - Gross margin for the full year was 62.3%, with a slight reduction due to higher material costs and tariffs [23] Business Line Data and Key Metrics Changes - Domestic core business grew 18% year-over-year in Q4, while international core business saw an impressive growth of 71% [20][22] - The PST business decreased by 30% year-over-year due to milestone-based revenue recognition timing [21] - The recurring global patient base increased by approximately 20% to 59,000 patients [12] Market Data and Key Metrics Changes - The SCIG market grew approximately 10% in 2025, with KORU's domestic and international core businesses outperforming this growth [8][20] - In Europe, KORU's market share in the SCIG pump and consumables market increased from 10% in 2024 to 20% in 2025 [15] - The overall European SCIG market is valued at approximately $50 million, with significant growth potential as the market shifts from vial-based delivery to prefilled syringes [15][16] Company Strategy and Development Direction - KORU is focused on three strategic pillars: protecting and growing the core domestic business, expanding internationally, and enabling more drugs to reach more patients [10][31] - The company aims to diversify its business with new product developments and collaborations, including entry into oncology and nephrology markets [12][13] - KORU plans to leverage its strong position in the SCIG market, which is projected to grow at 8%-10% over the next five years [11][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, with 2026 revenue guidance set at $47.5 million to $50 million, representing a growth of 15%-22% [10][25] - The company is prepared for geopolitical risks and anticipates a ramp-up in revenue in the second half of 2026 as new products are introduced [26] - Management highlighted the importance of operational excellence programs to offset external cost pressures [27] Other Important Information - The CEO announced retirement effective June 30, 2026, with the Chief Commercial Officer set to succeed [4][5] - KORU received EU MDR certification for the Freedom60 system, enabling prefilled syringe compatibility, which is expected to enhance market penetration [9][29] Q&A Session Summary Question: What does the Freedom60 product do for the market? - The Freedom60 opens up a $50 million total addressable market in Europe, with significant share gain potential as the company moves from 10% to 20% market share [35] Question: Can you provide more detail on the guidance range? - The guidance range is influenced by the speed of prefill conversions and new drug approvals, with potential impacts from geopolitical factors [66] Question: What is the growth opportunity in Japan? - Japan is seen as a significant market with potential for half a million to a million-dollar opportunity as the market shifts towards home care [70]

Limoneira Company (NasdaqGS:LMNR) Q1 2026 Earnings call March 12, 2026 04:30 PM ET Speaker5Good evening, and welcome to Limoneira's first quarter 2026 financial results conference call. At this time, all participants are on a listen-only mode. A brief question-and-answer session will follow the formal presentation. It is now my pleasure to introduce your host, John Mills with ICR. Thank you. You may begin.Speaker3Great. Thank you. Good afternoon, everyone, and thank you for joining us for Limoneira's first ...

Universal Electronics (NasdaqGS:UEIC) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Speaker0Good afternoon. My name is Daniel, and I will be your conference operator today. Now I would like to welcome everyone to Universal Electronics fourth quarter and year-end 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question at that time, please press s ...

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were $2.2 million, a 76% increase from $1.3 million in Q4 2024, primarily due to higher unit sales of M400 smart glasses and increased engineering services sales [20] - For the full year 2025, total revenues were $6.3 million, up 9% from $5.8 million in 2024 [21] - The overall gross loss for 2025 was $1.1 million, significantly improved from a loss of $5.6 million in 2024, mainly due to lower inventory obsolescence reserves [22] - The net loss attributable to common shareholders for Q4 2025 was $8.7 million or $0.12 per share, compared to a net loss of $13.7 million or $0.16 per share in Q4 2024 [26] - For the full year 2025, the net loss was $32.3 million or $0.42 per share, down from $73.5 million or $1.08 per share in 2024 [27] Business Line Data and Key Metrics Changes - Product sales increased by 4% year-over-year, driven by greater unit sales of M400 products [22] - Engineering services sales for 2025 were $1.6 million, up 27% from $1.3 million in 2024 [22] - Research and development expenses rose 31% to $12.6 million in 2025, primarily due to increased external development costs for the new LX1 smart glasses [23] Market Data and Key Metrics Changes - The enterprise markets are becoming more mature and ROI-driven, with customers focused on solutions that improve workflow efficiency and enhance safety [17] - The defense and security agencies segment is seeing growth in active programs and discussions, with a mix of activities including active deliveries and contracted programs [12] Company Strategy and Development Direction - The company is focusing on its OEM products and waveguide technology as key growth engines, with a strategic shift towards more selective investment in branded products [6][9] - The long-term growth strategy is centered around engineering services, with an emphasis on partnerships and customized solutions for large-scale enterprises [8] - The company aims to leverage its waveguide technology for scalable production, positioning itself in the next generation of AI and AR-enabled smart glasses [8][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the OEM business and waveguide technology, expecting revenues from these areas to surpass those from the branded enterprise side by the end of 2026 [33] - The company anticipates multiple new business partnerships and orders throughout 2026, indicating a strong pipeline of opportunities [35] - Management highlighted the importance of strategic relationships and the value created through improved business structure and operational capabilities [41] Other Important Information - The company ended 2025 with a cash position of $21.2 million, an increase from $18.2 million in 2024, and no current or long-term debt [27][28] - Inventory levels improved, with net inventory declining to $2.2 million as of December 31, 2025, compared to $4.8 million at the end of 2024 [28] Q&A Session Summary Question: Expectations for 2026 revenue and significant revenue sources - Management expects the OEM and waveguide business to grow quarter after quarter, potentially surpassing revenues from the branded enterprise side by year-end [33] Question: Anticipation of additional orders and announcements in 2026 - Management indicated that there would likely be several announcements regarding orders and partnerships throughout 2026, contributing to new business opportunities [35]

Financial Data and Key Metrics Changes - Inovio reported a net income of $3.8 million or $0.06 per share for Q4 2025, compared to a net loss of $84.9 million or $1.81 per share for the full year 2025 [25][26] - Total operating expenses decreased from $20.5 million in Q4 2024 to $17.5 million in Q4 2025, and full-year operational expenses dropped 23% from $112.6 million in 2024 to $86.9 million in 2025 [25][26] - Cash equivalents and short-term investments decreased to $58.5 million as of December 31, 2025, down from $94.1 million a year earlier [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - The company is also advancing other promising candidates in its pipeline, including INO-5412 for glioblastoma, through partnerships [8][21] Market Data and Key Metrics Changes - The FDA accepted the BLA for INO-3107 under the Accelerated Approval Program, with a PDUFA target date set for October 30, 2026 [5][6] - Market research indicates strong physician interest in INO-3107 due to its efficacy and tolerability, with a significant reduction in surgeries for patients [16][35] Company Strategy and Development Direction - The company is focused on optimizing resources to extend its cash runway towards the October PDUFA date while advancing its pipeline [24][58] - Inovio aims to leverage partnerships to enhance its research capabilities and expedite the development of its DNA medicines platform [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [5][11] - The company is preparing for discussions with the FDA regarding the accelerated approval and is optimistic about the potential for INO-3107 to become a preferred treatment option [29][35] Other Important Information - The company has reduced headcount by approximately 15% to conserve financial resources and extend its cash runway [24] - The recent market research supports the belief that INO-3107 could become the preferred treatment based on its efficacy and simple treatment regimen [16][35] Q&A Session Summary Question: What additional data is needed for FDA conversations regarding accelerated approval? - No new clinical data is required, but new documentation has been submitted to the FDA [28][29] Question: How would a six-month priority review timeline impact launch preparations? - The focus is currently on ensuring alignment with the FDA for accelerated approval, with commercial preparations well advanced [32][33] Question: What feedback was received from KOLs and patients regarding recent publications? - Research indicates a strong preference for INO-3107 due to its efficacy and tolerability, with significant reductions in surgeries reported [35][36] Question: How is the company using learnings from competitors for launch strategy? - The company is observing competitor strategies and leveraging the experience of its commercial partners to prepare for launch [41][43] Question: Can you explain the rationale behind the Akeso partnership? - The partnership aims to enhance immune responses against tumor-associated antigens through a dual PD-1/CTLA-4 blockade [46][47]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $123.5 million, up from $114.3 million in Q4 2024, representing an increase of 10.5% [29] - Company-operated restaurant revenue increased by 7.1% to $102.4 million from $95.6 million in the same period last year [29] - Adjusted EBITDA for Q4 2025 was $16.9 million compared to $14.3 million in Q4 2024 [36] - GAAP net income for Q4 was $6.5 million or $0.22 per diluted share, compared to $6 million or $0.20 per diluted share in the prior year [35] Business Line Data and Key Metrics Changes - Franchise revenue increased by 15.5% to $13 million during Q4, driven by a 3.2% increase in comparable restaurant sales [30] - The growth in comparable restaurant sales included a 2.7% increase in average check size, partially offset by a 2.3% decrease in transactions [30] Market Data and Key Metrics Changes - System-wide comparable store sales for the first quarter of 2026 increased by 2.4%, consisting of a 1.8% increase in company-operated restaurants and a 2.8% increase in franchise restaurants [31] Company Strategy and Development Direction - The company aims to drive sustainable traffic growth while maintaining margin discipline and unit economic improvements achieved over the past two years [6] - The focus is on a five-pillar strategy that includes culinary innovation, operational excellence, and digital engagement to strengthen the brand's position [7][14] - The company plans to open approximately 18-20 new restaurants in 2026, with a significant portion outside California [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the consumer's demand for quality food at a good value, noting that consumers are increasingly budget-conscious [42] - The company is optimistic about its growth trajectory, supported by a healthy pipeline of franchise partners and operational improvements [56][58] Other Important Information - The company completed 69 planned remodels in 2025 and plans to remodel 25-35 company-operated restaurants in 2026 [26] - The company has made substantial technology investments, including upgrading to a cloud-enabled point of sale platform [23] Q&A Session Summary Question: What is the underlying demand in the current consumer environment? - Management noted that consumers are looking for great food at a great value and are increasingly budget-conscious, responding positively to value-driven offerings [42] Question: How is the company managing menu innovation and marketing? - The company is pacing and sequencing its menu innovations thoughtfully, ensuring that new items replace older ones to manage complexity [46][47] Question: What is the mix of growth between existing franchisees and new partners? - Management indicated a healthy mix of growth from existing franchise partners and new partners, with a focus on expanding the franchise pipeline [56] Question: What gives the company confidence in its multi-year guidance? - The company has stabilized and improved margins and profitability, allowing for longer-term planning and investment in growth initiatives [58] Question: What is the plan for managing debt and cash flow? - The company plans to invest cash flow into business growth while evaluating potential returns to shareholders in the future [73]

Financial Data and Key Metrics Changes - Consolidated revenue for 2025 was $493 million, a 3% increase from $480 million in 2024 [19] - Gross margin improved to 7% of revenue, up from a negative 12% in 2024, reflecting a $90 million increase in total gross margin [19][16] - Adjusted EBITDA for 2025 was $5 million, a significant improvement from a negative $61 million in 2024 [20] Business Line Data and Key Metrics Changes - Revenue from Shimmick projects was $395 million, a 12% increase year-over-year, representing 75% of total revenue [2] - Non-core project revenue decreased to $96 million from $125 million in 2024, indicating a focus on winding down low-margin projects [19][3] - Gross margin for Shimmick projects was 10%, a 400 basis point improvement over the previous year [3] Market Data and Key Metrics Changes - Backlog grew to $793 million, with a book-to-burn ratio of 1.4 times, indicating strong demand and project wins [18][5] - The company expects a robust pipeline with $600 million to $1 billion in bidding volumes per month [6][4] - New awards booked during Q4 2025 were $135 million, a sequential increase from Q3 2025 [18] Company Strategy and Development Direction - The company is focused on three strategic pillars: growing the top line, winding down legacy low-margin projects, and driving operational improvements [2][23] - Emphasis on collaborative delivery methods, such as progressive design-build and construction manager/general contractor, to enhance project execution and margins [8][9] - The company aims to position itself as a top infrastructure provider by aligning project selection with core strengths and market opportunities [25][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, projecting revenue growth between 12% and 22%, with adjusted EBITDA expected to increase significantly [22] - The market remains healthy, with strong demand in core sectors such as water and electrical construction, particularly in California and Texas [34][4] - Management highlighted improvements in operational efficiency and talent retention as key factors for future success [11][12] Other Important Information - The company ended 2025 with total liquidity of $44 million, consisting of $20 million in cash and $24 million available under credit agreements [18] - The company is actively pursuing opportunities in the data center market, which is expected to contribute significantly to future revenue [9] Q&A Session Summary Question: How will gross margins be impacted by new project awards? - Management expects gross margins to increase, influenced by the mix of projects, with a focus on maintaining efficient SG&A expenses [30][31] Question: What is the outlook for backlog and overall spending in key markets? - Management indicated strong visibility in California and Texas, with no shortage of opportunities expected in the next 12-24 months [34][35] Question: What is the guidance for 2026, particularly regarding non-core revenue? - Management anticipates burning through most non-core work, which currently represents about 11% of the backlog, with minimal impact on overall margins [43][44] Question: Can you provide more details on the electrical infrastructure projects? - The electrical business is seeing strong bidding activity, with projects ranging from $5 million to $200 million, particularly in Texas and California [46][47] Question: How is the company managing the completion of legacy non-core projects? - Management reported that only two non-core projects remain active, with a focus on wrapping them up efficiently this year [48][49]

Ulta Beauty (NasdaqGS:ULTA) Q4 2026 Earnings call March 12, 2026 04:30 PM ET Speaker9Good afternoon, everyone. My name is Layla, and I will be your conference operator today. At this time, I would like to welcome you to Ulta Beauty's fourth quarter and fiscal 2025 earnings call. This conference is being recorded, and all lines have been placed on mute to prevent any background noise. After the speakers' prepared remarks, there will be a question and answer session. At this time, I would like to turn the cal ...